Study of GSK5460025 for advanced solid tumors
Part of Cancer, Digestive system, Women’s health & pregnancy clinical trials.
This trial tests a new drug, GSK5460025, alone or with other cancer treatments, for people with advanced solid tumors that have spread or cannot be removed by surgery. It may help those whose cancer has a specific genetic feature (dMMR or MSI-H) or who have not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor that has spread or cannot be removed by surgery.
- Your cancer has a specific genetic feature called dMMR or MSI-H, or you are willing to be tested for it.
- You are able to provide a tissue sample from your tumor (either from a past biopsy or a new one).
- You have recovered from side effects of previous cancer treatments.
- You are well enough to perform daily activities (ECOG score 0-2) and expected to live at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, GSK5533524, alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapies. It aims to find out if the drug is safe and shows early signs of working.
This study tests a new drug called GSK5764227 for people with advanced solid tumors. It aims to see if the drug is safe and works against cancer that has stopped responding to other treatments.
This trial tests a new investigational drug called GSK5764227 when given along with standard cancer treatments or other drugs for people with advanced colorectal or prostate cancer that has spread and cannot be removed by surgery.
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
This trial tests a new drug, MK-6204, in people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
This trial tests a new drug called JMKX005425 for people with advanced solid tumors that have a specific genetic feature called MSI-H or dMMR. If you have this feature and your cancer has not responded to other treatments, this study may offer a new option.
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.